3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
8
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Sarcoma
7
Lymphoma, Large B-Cell, Diffuse
6
Osteosarcoma
3
Lymphoma, B-Cell
3
Sarcoma, Ewing
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Penile Neoplasms
2
Neurofibrosarcoma
2
Liposarcoma
2
Hemangiosarcoma
2
Fibrosarcoma
2
Burkitt Lymphoma
2
Wilms Tumor
1
Vascular Neoplasms
1
Teratoma
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Clear Cell
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pleuropulmonary blastoma
1
Neuroblastoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Adipose Tissue
1
Neoplasm Metastasis
1
Myoepithelioma
1
Lymphoma, T-Cell, Peripheral
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Ifosfamide
×
Clear all
NCT05533775
2026-05-04
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2
Recruiting
65 enrolled